www.neurologiepropraxi.cz / Neurol. praxi. 2023;24(2):132-139 / NEUROLOGIE PRO PRAXI 139 Z POMEZÍ NEUROLOGIE Covid-19 a jeho vliv na (chronickou) bolest – postřehy z praxe curve: a model for the safe reintegration of elective interventional pain procedures. Pain Phys. 2020;23:S449-S451. 9. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220-32. 10. Kaur A, Singh L, Singh N, et al. Ameliorative effect of imperatorin in chemically induced fibromyalia: Role of NMDA/ NFkB mediated downstream signaling. Biochem Pharmacol. 2019;166:56-69. 11. Kemp HL, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. Brit J Anaesth. 2020;125(4): 436-40. 12. Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encefalomyelitis/chronic fatigue syndrome? Front Med. 2021;7:606824. 13. Lacasse A, Pagé MG, Dassieu L, et al. Impact of the COVID-19 pandemic on the pharmacological, physical, and psychological treatment of pain: findings from the Chronic pain & COVID-19 Pan‑Canadian Study. Pain Rep. 2021_6_e891. 14. Lopez‑Leon S, Wegman‑Ostrosky T, Perelman C, et al. More than 50 long‑term effects of COVID-19: a systematic review and meta‑analysis. Sci Rep. 2021;11(1):16144. 15. Meo SA, Bukhari IA, Akram J, et al. COVID-19 Vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25:1663-69. 16. Meyer‑Friessem CH, Giertmühlen J, Baron R, et al. Pain during and after COVID-19 in Germany and worldwide: a narrative review of current knowledge. Pain Rep. 2021;6:e893. 17. Mun CJ, Campbell CM, McGill LS, Aaron RV. The early impact of COVID-19 on chronic pain: A cross‑sectional investigation of a large online sample of indiviuals with chronic pain in the United States, April to May, 2020. Pain Med. 2021;22(2):470-80. 18. Murphy MT, Latif U. Pain during COVID-19: A comprehensive review and guide for the interventionalist. Pain Pract. 2021;21(1):132-43. 19. Rýdlová J, Fabiánová J. Myalgická encefalomyelitida – praktická aplikace Mezinárodních konsenzuálních kritérií. Med praxi. 2013;10(4):160-62. 20. Salaffi F, Giorgi V, Sirotti S, et al. The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. Clin Exp Rheumatol. 2020. PMID: 33200740. 21. Serrano‑Ibanez ER, Esteve R, Ramírez‑Maestre C, et al. Chronic pain in the time of COVID-19: Stress aftermath and central senzitization. Brit J Health Psychol. 2020; doi: 10.1111/ bjhp.12483. 22. Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta‑analysis. Front Immunol. 2021. doi: 10.3389/. fimmu.2021.714170. PŘEDNÁŠKY Význam studie PEARL pro klinickou praxi – MUDr. Jolana Marková, FEAN Medication overuse headache a role anti-CGRP – MUDr. Petra Migaľová Lékové interakce migréna a RS – update – PharmDr. Josef Suchopár Výhody exibility podání fremanezumabu u našich pacientů – MUDr. Monika Záhumenská ODBORNÝ GARANT MUDr. Jolana Marková, FEAN Neurologická klinika, Fakultní Thomayerova nemocnice v Praze PARTNER POČET KREDITŮ 2 Registrace ZDARMA TERMÍN prosinec 2022 až listopad 2023 dostupný na online.solen.cz On-line kurz pro praktické neurology Trendy v léčbě migrény 3 2022 ON LINE KURZ
RkJQdWJsaXNoZXIy NDA4Mjc=